Valproic Acid Combo Therapy Fails to Improve Survival of SMA Type I Infants, Clinical Trial Shows Written by | Valproic acid (VPA) combined with L-carnitine previously suggested as a potential therapy for infants with spinal muscular atrophy (SMA) does not improve the survival of SMA type I patients, according to the results of the CARNIVAL clinical trial
South America presents a different access pattern, because Brazil saw strong GLP-1 demand growth after patent expiry, and Argentina already had domestic semaglutide biosimilar activity with partial insurer reimbursement for documented diabetes treatment
Mucoadhesive phenylboronic acid conjugated chitosan oligosaccharide-vitamin E copolymer for topical ocular delivery of voriconazole: synthesis, in vitro/vivo evaluation, and mechanism
Rousseau, E
The underlying pathophysiology of OCD involves a complex interplay of genetic, neurobiological, and environmental factors
A 2023 study published in The New England Journal of Medicine reported 19 cases of cardiac arrhythmia in patients, mainly at the highest doses, but 17 continued on with treatment